This article is more than 5 years old. Information may no longer be current.
QLT to investigate triamcinolone as adjunct to PDT
Click Here to Manage Email Alerts
VANCOUVER — A preservative-free formulation of triamcinolone acetonide will be tested as an adjunct to verteporfin photodynamic therapy for patients with wet age-related macular degeneration in a trial recently announced by QLT.
The multi-center, randomized, prospective, phase-3 trial, a cooperative research and development agreement between QLT and the National Eye Institute, will enroll about 300 patients, QLT noted in a press release. Under terms of the agreement, QLT will provide funding for the combination clinical trial and will assume manufacturing the preservative-free drug, which was developed by researchers at the NEI. In return, QLT will gain the option to an exclusive license for certain rights to the drug in combination with verteporfin therapy. The National Eye Institute will be responsible for the actual clinical trial, the press release said.
Verteporfin photodynamic therapy is jointly marketed by QLT and Novartis as Visudyne.